In summary, the present study firstly provides the evidence that KDM5C alterations were associated with enhanced tumor immunogenicity and inflamed anti-tumor immunity, which result in prolonged OS in cancer patients treated with ICIs. The gene discussed is KDM5C; the disease is cancer.